The New England Journal of Medicine published a study showing PSA screenings reduced the mortality rate of prostate cancer by 29 percent.
The study “Prostate-Cancer Mortality at 11 Years of Follow-up” underscored the power of PSA-based screenings in saving lives from prostate cancer.
The European Randomized Study of Screening for Prostate Cancer (ERSPC) studied 182,160 men between 50 and 74 years old, with a core age group of 162,388 men 55 to 69 years old.
Men randomly assigned to the screening group were offered PSA screening and men in the control group were not offered screening.
The results showed that for all patients, there was a 21% survival advantage, and more importantly, for those with the longest follow-up (over 10 years) this increased to 38%.
“This study validates what we have seen over the past two decades caring for patients with prostate cancer. We are detecting cancer earlier and saving lives,” said Urology Care Alliance physician Russell M. Freid, MD. “It also reinforces our belief the decision on how to screen and treat prostate cancer should be made by patients and their doctors.”